Evidence map›Paper›PMID 29063617›Full record

ReviewThe Journal of physiology2018

Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin.

I-Shan Chen, Yoshihiro Kubo

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in The Journal of physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05076253 (Efficacy and Safety of Ivermectin in Treatment of Mild to Moderate COVID-19 Infection), which is not on this map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05076253 phase1 / phase2completednot on this mapstarted 2021, after this paper: background citation

Efficacy and Safety of Ivermectin in Treatment of Mild to Moderate COVID-19 Infection: a Randomized ,Double Blind,Placebo,Controlled Trial

TypeinterventionalSponsorBangkok Metropolitan Administration Medical College and Vajira HospitalRan2021 to 2021Enrolled72ConditionsSafety, SARS-CoV2 Infection, Ivermectin Poisoning, Effect of DrugArmsIvermectin, Placebo
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 111 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Potential ofMetabolites · 2024
    Review
  14. Impact ofInsects · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Impact of Ivermectin on the Gut Microbial Ecosystem.International journal of molecular sciences · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

I-Shan ChenDivision of Biophysics and Neurobiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, Okazaki, 444-8585, Japan.ORCID 0000-0003-3204-3921
Yoshihiro KuboDivision of Biophysics and Neurobiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, Okazaki, 444-8585, Japan.
The Graduate University for Advanced Studies, SOKENDAI · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ivermectin (IVM) is an antiparasitic drug that is used worldwide and rescues hundreds of millions of people from onchocerciasis and lymphatic filariasis. It was discovered by Satoshi Ōmura and William C. Campbell, to whom the 2015 Nobel Prize in Physiology or Medicine was awarded. It kills parasites by activating glutamate-gated Cl

Indexed as

Ion Channel GatingAnimalsAntiparasitic AgentsChloride ChannelsG Protein-Coupled Inwardly-Rectifying Potassium ChannelsHumansIvermectinReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearReceptors, Purinergic P2X4Antiparasitic AgentsChloride Channelsglutamate-gated chloride channelsG Protein-Coupled Inwardly-Rectifying Potassium ChannelsIvermectinReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearReceptors, Purinergic P2X4ion channelIvermectinReceptor

Identifiers

PMID29063617
PMCPMC5978302
OpenAlexW2765521280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.